Lv1
70 积分 2024-11-03 加入
Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine
15天前
已完结
Menin inhibitors for adult acute myeloid leukemia: 2025 update
1个月前
已完结
Ziftomenib: First Approval
2个月前
已完结
Revumenib Monotherapy in Patients with Relapsed/Refractory KMT2Ar Acute Leukemias: Efficacy and Safety Results from the Augment-101 Phase 1/2 Study
4个月前
已完结
Mutational spectrum of de novo NPM1-mutated acute myeloid leukemia patients older than 75 years
5个月前
已完结
Impact of secondary‐type mutations in NPM1 mutated AML
5个月前
已完结
Phase 1 Results: First-in-Human Phase 1/2 Study of the Menin-MLL Inhibitor Enzomenib (DSP-5336) in Patients with Relapsed or Refractory Acute Leukemia
9个月前
已完结
Bleximenib Dose Optimization and Determination of RP2D from a Phase 1 Study in Relapsed/Refractory Acute Leukemia Patients with KMT2A and NPM1 Alterations
9个月前
已关闭
The role of menin inhibitors in acute myeloid leukemia
10个月前
已关闭
Epigenetic Regulation of Non-canonical Menin Targets Modulates Menin Inhibitor Response in Acute Myeloid Leukemia
10个月前
已完结
皖公网安备34019202002308
